Mats-Olof Wallin

Director of Finance/CFO at OxThera AB

73 year

Health Technology

Consumer Services

Mats-Olof Wallin active positions

Companies	Position	Start	End
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Director of Finance/CFO	2019-12-31	-

Companies	Position	Start	End
KARO PHARMA AB (PUBL)	Director of Finance/CFO	2017-12-31	2019-09-30
SWEDISH ORPHAN BIOVITRUM AB	Director of Finance/CFO	2013-04-07	2018-07-19
BIOTAGE AB	Director of Finance/CFO	2010-05-16	2011-12-31
BIOTAGE AB	Public Communications Contact	2010-05-16	2011-12-31

University of Uppsala

Undergraduate Degree

International

Sweden

Operational

Director of Finance/CFO	4
Public Communications Contact	1
Undergraduate Degree	1

Sectoral

Health Technology	5
Consumer Services	2

Positions held

Active

Inactive

Listed companies

Private companies

Private companies	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology

Private companies

Health Technology